PTC Therapeutics (PTCT) EVP sells stock to cover RSU tax withholding

Rhea-AI Filing Summary

PTC Therapeutics executive Golden Lee Scott, EVP & Chief Medical Officer, reported automatic sales of company stock tied to RSU vesting. On January 6, 2026, 1,340 shares of PTC Therapeutics common stock were sold at $76.95 per share in a transaction marked as a sale, leaving 93,936 shares beneficially owned directly. On January 7, 2026, a further 642 shares were sold at $77.48 per share, resulting in direct beneficial ownership of 93,294 shares.

According to the footnotes, both transactions represent shares automatically sold under an irrevocable "sell to cover" election made when the RSU grants were accepted, in order to satisfy tax withholding obligations upon vesting of 5,000 RSUs from a January 3, 2025 grant of 20,000 RSUs and 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs.

Insider Trade Summary

Net Seller: 1,982 shares ($152,855)

Net Sell 2 txns

Insider Golden Lee Scott

Role EVP & CHIEF MEDICAL OFFICER

Sold 1,982 shs ($153K)

Type	Security	Shares	Price	Value
Sale	Common Stock	642	$77.48	$50K
Sale	Common Stock	1,340	$76.95	$103K

Holdings After Transaction: Common Stock — 93,294 shares (Direct)

Footnotes (1)

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,000 RSUs from a January 3, 2025 grant of 20,000 RSUs. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Golden Lee Scott

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S		1,340(1)	D	$76.95	93,936	D
Common Stock	01/07/2026		S		642(2)	D	$77.48	93,294	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,000 RSUs from a January 3, 2025 grant of 20,000 RSUs.

2. Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs.

	/s/ Avraham S. Adler, Attorney-in-Fact	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PTC Therapeutics (PTCT) report in this Form 4?

The filing reports that Golden Lee Scott, EVP & Chief Medical Officer of PTC Therapeutics, Inc., sold shares of the company’s common stock in two separate transactions on January 6, 2026 and January 7, 2026, related to tax withholding on vesting RSUs.

How many PTC Therapeutics shares did Golden Lee Scott sell and at what prices?

Golden Lee Scott sold 1,340 shares of PTC Therapeutics common stock on January 6, 2026 at $76.95 per share, and 642 shares on January 7, 2026 at $77.48 per share, with both transactions reported as sales of non-derivative securities.

How many PTC Therapeutics shares does the reporting person own after these transactions?

After the January 7, 2026 transaction, Golden Lee Scott is reported to beneficially own 93,294 shares of PTC Therapeutics common stock directly, according to the Form 4.

Were the PTC Therapeutics share sales discretionary or related to tax withholding on RSUs?

The footnotes state that the reported share sales were automatically executed under an irrevocable “sell to cover” election made when the RSU grants were accepted, to satisfy tax withholding obligations upon vesting of RSUs granted in January 2023 and January 2025.

What RSU grants are connected to the reported PTC Therapeutics share sales?

The January 6, 2026 sale is tied to the vesting of 5,000 RSUs from a January 3, 2025 grant of 20,000 RSUs. The January 7, 2026 sale is tied to the vesting of 2,666 RSUs from a January 5, 2023 grant of 10,640 RSUs, as described in the footnotes.

Is the PTC Therapeutics Form 4 filed by an individual or multiple reporting persons?

The document indicates it is a Form filed by one reporting person, namely Golden Lee Scott, who is identified as an officer with the title EVP & Chief Medical Officer of PTC Therapeutics, Inc.